[Skip to Content]
[Skip to Content Landing]
Views 281
Citations 0
Invited Commentary
December 2016

Radiotherapy Deferral in Medulloblastoma

Author Affiliations
  • 1Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas
  • 2Department of Radiation Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland
JAMA Oncol. 2016;2(12):1582. doi:10.1001/jamaoncol.2016.2546

Radiotherapy (RT) is an important component in the treatment of medulloblastoma. For children 3 years or older, the combination of maximal safe resection, craniospinal irradiation, primary site RT boost, and chemotherapy is considered standard treatment. In this issue, Kann et al1 report that about 15% of children ages 3 to 8 years with medulloblastoma did not get RT within 90 days of surgery using the National Cancer Data Base (NCDB) registry. For these patients, 5-year overall survival was worse compared with those receiving RT within 90 days of surgery (82% vs 63.4%; P < .001).

First Page Preview View Large
First page PDF preview
First page PDF preview